In a move that may help make insulin more affordable for people with diabetes, the FDA has approved the first product that’s interchangeable with and biosimilar to the long-acting insulin glargine, marketed as Lantus.
The approval will allow pharmacists to substitute the biosimilar, insulin glargine-yfgn, for brand-name insulin glargine without consulting a patient’s physician, the same as they do for generic drugs. Patients’ savings could be substantial. With a discount card and no insurance coverage, the cash price of insulin glargine-yfgn is about $112 for 10 mL compared with $306 for insulin glargine.
Kuehn BM. First Interchangeable Biosimilar Insulin Drug Is Approved. JAMA. 2021;326(9):801. doi:10.1001/jama.2021.14729
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: